The Role of Co-Stimulation in Chronic GVHD

There are several FDA-approved treatments with meaningful impacts and improved outcomes in patients with steroid refractory chronic GVHD. Abadisept was initially approved back in 2005 for the treatment of rheumatoid arthritis, but it's also used to treat other rheumatological conditions. It's a recombinant fusion protein that binds to CD80 and CD86 on antigen-presenting cells which attenuates the CD28-mediated activation of T-cells. The most common underlying primary diseases were AML in 46% of the patients, and MDS in 20%.